NasdaqCM:HSKA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. More Details


Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Heska's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HSKA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.7%

HSKA

-1.7%

US Medical Equipment

-0.8%

US Market


1 Year Return

39.2%

HSKA

16.5%

US Medical Equipment

13.8%

US Market

Return vs Industry: HSKA exceeded the US Medical Equipment industry which returned 16.5% over the past year.

Return vs Market: HSKA exceeded the US Market which returned 13.8% over the past year.


Shareholder returns

HSKAIndustryMarket
7 Day1.7%-1.7%-0.8%
30 Day-4.6%-3.5%-5.7%
90 Day5.9%12.2%8.6%
1 Year39.2%39.2%17.5%16.5%16.4%13.8%
3 Year8.4%8.4%70.0%65.6%36.9%27.8%
5 Year222.2%222.2%139.5%121.3%85.0%64.2%

Price Volatility Vs. Market

How volatile is Heska's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Heska undervalued compared to its fair value and its price relative to the market?

3.44x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: HSKA ($98.62) is trading above our estimate of fair value ($75.19)

Significantly Below Fair Value: HSKA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: HSKA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: HSKA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HSKA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HSKA is good value based on its PB Ratio (3.4x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is Heska forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

104.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HSKA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: HSKA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: HSKA's is expected to become profitable in the next 3 years.

Revenue vs Market: HSKA's revenue (16.6% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: HSKA's revenue (16.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HSKA's Return on Equity is forecast to be low in 3 years time (4.5%).


Next Steps

Past Performance

How has Heska performed over the past 5 years?

-33.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HSKA is currently unprofitable.

Growing Profit Margin: HSKA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HSKA is unprofitable, and losses have increased over the past 5 years at a rate of 33.9% per year.

Accelerating Growth: Unable to compare HSKA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HSKA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: HSKA has a negative Return on Equity (-5.23%), as it is currently unprofitable.


Next Steps

Financial Health

How is Heska's financial position?


Financial Position Analysis

Short Term Liabilities: HSKA's short term assets ($158.4M) exceed its short term liabilities ($32.9M).

Long Term Liabilities: HSKA's short term assets ($158.4M) exceed its long term liabilities ($74.1M).


Debt to Equity History and Analysis

Debt Level: HSKA's debt to equity ratio (18.5%) is considered satisfactory.

Reducing Debt: HSKA's debt to equity ratio has increased from 3.3% to 18.5% over the past 5 years.

Debt Coverage: HSKA's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if HSKA's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Heska current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HSKA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HSKA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HSKA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HSKA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: HSKA is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HSKA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Kevin Wilson (48 yo)

6.5yrs

Tenure

US$609,296

Compensation

Mr. Kevin S. Wilson has been President of Heska Corporation since February 24, 2013. Mr. Wilson has been Chief Executive Officer of Heska Corporation since March 31, 2014. He served as Chief Operating Offi ...


CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD609.30K) is below average for companies of similar size in the US market ($USD3.05M).

Compensation vs Earnings: Kevin's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Wilson
CEO, President & Director6.5yrsUS$609.30k2.49%
$ 23.2m
Catherine Grassman
Executive VP & CFO1.33yrsUS$1.47m0.039%
$ 367.1k
Nancy Wisnewski
Executive VP & COO1.08yrsUS$311.22k0.51%
$ 4.8m
Steven Eyl
Chief Commercial Officer0.42yrUS$310.34k0.14%
$ 1.3m
Christopher Sveen
Executive VP0.42yrno data0.00015%
$ 1.4k
Jon Aagaard
Director of Investor Relationsno datano datano data
Jason Aroesty
Executive Vice President of International Diagnostics2.42yrsUS$3.56m0.26%
$ 2.5m
Daniel Pollack
VP of Imaging Operationsno datano datano data
Eleanor Baker
VP, General Counsel & Secretaryno datano data0.0020%
$ 18.7k
Laurie Peterson
Vice President of Heska Des Moinesno datano datano data

1.2yrs

Average Tenure

48yo

Average Age

Experienced Management: HSKA's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Kevin Wilson
CEO, President & Director6.5yrsUS$609.30k2.49%
$ 23.2m
Mark Furlong
Independent Director1.5yrsUS$108.80k0.031%
$ 291.6k
Scott Humphrey
Independent Chairman of the Board1.92yrsUS$134.48k0.054%
$ 504.1k
Sharon Larson
Independent Director9.17yrsUS$121.98k0.072%
$ 674.5k
Stephen Davis
Director0.083yrno data0.014%
$ 126.7k
David Sveen
Independent Director6.83yrsUS$113.48k0.35%
$ 3.2m
Bonnie Trowbridge
Independent Director5.67yrsUS$125.98k0.043%
$ 403.3k

5.7yrs

Average Tenure

61yo

Average Age

Experienced Board: HSKA's board of directors are considered experienced (5.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HSKA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.1%.


Top Shareholders

Company Information

Heska Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Heska Corporation
  • Ticker: HSKA
  • Exchange: NasdaqCM
  • Founded: 1988
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$931.339m
  • Shares outstanding: 9.44m
  • Website: https://www.heska.com

Number of Employees


Location

  • Heska Corporation
  • 3760 Rocky Mountain Avenue
  • Loveland
  • Colorado
  • 80538
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HSKANasdaqCM (Nasdaq Capital Market)YesPublic Common StockUSUSDJul 1997
HSKNDB (Deutsche Boerse AG)YesPublic Common StockDEEURJul 1997

Biography

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The compa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/28 04:46
End of Day Share Price2020/09/25 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.